Skip Navigation


Hum. Reprod. Advance Access originally published online on June 6, 2008
Human Reproduction 2008 23(8):1815-1819; doi:10.1093/humrep/den212
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
23/8/1815    most recent
den212v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by De Vos, A.
Right arrow Articles by Van der Elst, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Vos, A.
Right arrow Articles by Van der Elst, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Randomized sibling-oocyte study using recombinant human hyaluronidase versus bovine-derived Sigma hyaluronidase in ICSI patients

A. De Vos1,3, L. Van Landuyt1, H. Van Ranst1, A. Vandermonde1, V. D’Haese1, J. Sterckx1, P. Haentjens2, P. Devroey1 and J. Van der Elst1

1 Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, B-1090 Brussels, Belgium 2 Centre for Outcomes Research, Universitair Ziekenhuis Brussel, Laboratory for Experimental Surgery, Vrije Universiteit Brussel, Laarbeeklaan 101, B-1090 Brussels, Belgium

3 Correspondence address. Tel: +32-2-477-66-97; Fax: +32-2-477-66-92; E-mail: anick.devos{at}uzbrussel.be

BACKGROUND: The enzyme hyaluronidase from bovine origin is commonly used for oocyte–cumulus cell removal in ICSI. A recombinant human hyaluronidase (rHuPH20) has been introduced as a quality-controlled and safe alternative.

METHODS: In order to validate its effectiveness, a non-inferiority trial was started on sibling cumulus–oocyte complexes (135 ICSI patients). Oocyte denudation involved enzyme incubation under Pasteur pipetting, followed by further mechanical stripping. Primary end-points were oocyte intactness after ICSI and fertilization rate. Secondary end-points were embryo development and positive hCG.

RESULTS: Oocyte intactness after ICSI was 89.6% and 92.9% with rHuPH20 and bovine hyaluronidase, respectively [absolute difference –3.3% (–7.4 to 10.7)]. The fertilization rate was 73.9% after rHuPH20 and 77.1% after bovine hyaluronidase treatment [absolute difference –3.2% (–8.3 to 1.8)]. Embryo development was similar in both treatment groups up till Day 5. Positive hCGs were equally distributed over mixed transfers 21/45 (46.7%) and transfers of only embryos from rHuPH20 treatment 17/35 (48.6%) or transfers of only embryos from bovine hyaluronidase treatment 22/48 (45.8%).

CONCLUSIONS: Our results indicate that rHuPH20 is not inferior to bovine hyaluronidase for oocyte denudation, with regard to oocyte survival and fertilization. rHuPH20 treatment of human oocytes is compatible with good embryo development, with positive hCG results and with live birth.

Key words: cumulus cell removal/hyaluronidase/ICSI prospective study

Submitted on February 25, 2008; resubmitted on April 29, 2008; accepted on May 6, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.